clinical trial · NCT07600775
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)
Merck Sharp & Dohme LLC·phase1·not yet recruiting·n = 14
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure ProphylaxisMK-8527Rifampin
brief summary
Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI). The main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.
started
Sep 1, 2026
primary completion
Jan 19, 2027
completion
Jan 19, 2027
last updated
Aug 3, 2026
official title
An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol